Alendronate and Zoledronate — Competitive Intelligence Brief

Alendronate and Zoledronate (Alendronate and Zoledronate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Bone metabolism / Osteoporosis.

marketed Bisphosphonate Farnesyl pyrophosphate synthase (mevalonate pathway); hydroxyapatite binding Bone metabolism / Osteoporosis Small molecule

Target snapshot

Alendronate and Zoledronate (Alendronate and Zoledronate) — National Taiwan University Hospital. Bisphosphonates that inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and reducing osteoclast activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alendronate and Zoledronate TARGET	Alendronate and Zoledronate	National Taiwan University Hospital	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase (mevalonate pathway); hydroxyapatite binding
Boniva	IBANDRONIC ACID	Hoffmann La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Skelid	TILUDRONIC ACID		marketed	Bisphosphonate	72 kDa type IV collagenase	1997-01-01
Aredia	PAMIDRONIC ACID		marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	1991-01-01
Didronel	ETIDRONIC ACID	Procter And Gamble	marketed	Bisphosphonate		1977-01-01
FOSAMAX PLUS D	FOSAMAX PLUS D	Organon and Co	marketed	Bisphosphonate + vitamin D3 combination	Osteoclast proton pump (alendronate); vitamin D receptor (cholecalciferol)
Ibandronate IV	Ibandronate IV	National Taiwan University Hospital	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

1. · 2 drugs in this class
2. Amgen · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Sanofi · 2 drugs in this class
5. Ludwig-Maximilians - University of Munich · 2 drugs in this class
6. Chinese University of Hong Kong · 1 drug in this class
7. Chinese Society of Lung Cancer · 1 drug in this class
8. Aarhus University Hospital · 1 drug in this class
9. Eisai Inc. · 1 drug in this class
10. Daiichi Sankyo Co., Ltd. · 1 drug in this class